Faeth Therapeutics Inc (FTH): Next-Year EPS Estimate 77.57%
As of 2026-08-26, Faeth Therapeutics Inc (FTH) has a next-year EPS growth estimate of 77.57%. Featured in 4 EPS revision reports, most recently on 2026-06-25.
On 2026-08-21, analyst consensus for FTH's next-year EPS growth shifted from 77.36% to 77.57% — a positive change of 0.21 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at 10.13%.
What's Driving This
FTH stock has been rising primarily due to a significant upward revision to its next-year EPS growth estimate, which analysts raised from 88.60% to 72.99% on August 5, 2026, before lifting it further to 77.57%. The second-quarter 2026 financial results, reported around that time, likely served as the specific catalyst for the initial upgrade, as they provided a fundamental basis for improved expectations. Since the revision, the estimate has continued to climb over three consecutive trading sessions, adding net +4.24 percentage points and supporting further upside momentum.
Generated 2026-08-24 from news as of 2026-08-24
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 77.57%
- EPS growth this year
- 10.13%
- EPS next quarter (est)
- -$0.79
- Last price
- $33.97
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-26 | 77.57% | 10.13% | -$0.79 | $33.97 |
| 2026-08-25 | 77.57% | 10.13% | -$0.79 | $34.52 |
| 2026-08-24 | 77.57% | 10.13% | -$0.79 | $34.71 |
| 2026-08-23 | 77.57% | 10.13% | -$0.79 | $32.00 |
| 2026-08-21 | 77.57% | 10.13% | -$0.79 | $32.00 |
| 2026-08-20 | 77.36% | 10.22% | -$0.80 | $32.10 |
| 2026-08-19 | 77.36% | 10.22% | -$0.80 | $33.11 |
| 2026-08-18 | 77.36% | 10.22% | -$0.80 | $33.00 |
| 2026-08-17 | 77.36% | 10.22% | -$0.80 | $32.77 |
| 2026-08-16 | 77.36% | 10.22% | -$0.80 | $32.34 |
| 2026-08-14 | 77.36% | 10.22% | -$0.80 | $32.34 |
| 2026-08-13 | 77.36% | 10.22% | -$0.80 | $28.55 |
| 2026-08-12 | 77.36% | 10.22% | -$0.80 | $29.38 |
| 2026-08-11 | 77.36% | 10.22% | -$0.80 | $30.00 |
| 2026-08-10 | 77.36% | 10.22% | -$0.80 | $28.57 |
| 2026-08-09 | 74.16% | 21.34% | -$0.80 | $24.39 |
| 2026-08-07 | 73.33% | 25.08% | -$0.70 | $24.39 |
| 2026-08-06 | 73.33% | 25.08% | -$0.70 | $24.48 |
| 2026-08-05 | 72.99% | 22.02% | -$0.74 | $24.59 |
| 2026-08-04 | 88.60% | -209.12% | -$2.76 | $25.50 |
| 2026-08-03 | 88.17% | -208.68% | -$2.82 | $27.34 |
| 2026-08-02 | 88.17% | -208.68% | -$2.82 | $27.24 |
| 2026-07-31 | 88.17% | -208.68% | -$2.82 | $27.24 |
| 2026-07-30 | 88.67% | -236.92% | -$2.95 | $28.82 |
| 2026-07-29 | 88.67% | -236.92% | -$2.95 | $28.93 |
| 2026-07-28 | 88.67% | -236.92% | -$2.95 | $29.13 |
| 2026-07-27 | 95.08% | -691.77% | -$3.24 | $29.24 |
| 2026-07-26 | 95.08% | -691.77% | -$3.24 | $28.29 |
| 2026-07-24 | 95.08% | -691.77% | -$3.24 | $28.29 |
| 2026-07-23 | 95.08% | -691.77% | -$3.24 | $27.76 |
Reports Featuring FTH
- 2026-06-25
FTH Surges 69.8% on EPS Revision; LILA, CRMT Also Jump
- 2026-06-24
FTH Leads EPS Revision Rally with 68.9% Surge; CRMT, LILA Also Gain
- 2026-06-23
FTH +65%, CRMT +65% Lead EPS Revision Surge; RFIL +29%, LILA +24%
- 2026-06-22
Top EPS Revision Winners: OTLK Surges 66%, FTH Gains 60% on Estimate Hikes
Recent News
Screen Performance
Aggregate stats across all 2015 tickers our top-EPS-revision screen has flagged over the past 147 days.
- Median return since detection
- +3.0%
- % of tickers in the green
- 56%
- Median return on winners
- +20.0%
- Large revisions captured
- 1609
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Faeth Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-08-26, Faeth Therapeutics Inc (FTH) has a next-year EPS growth estimate of 77.57%, based on analyst consensus.
When was the latest EPS estimate revision for FTH?▾
The most recent revision occurred on 2026-08-21, when analysts adjusted the next-year EPS growth estimate from 77.36% to 77.57%.
What sector and industry does Faeth Therapeutics Inc belong to?▾
Faeth Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. FTH appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Faeth Therapeutics Inc (FTH) appears here because it was detected by our daily top-EPS-revision-performer screen.